PharmPK Discussion - Snapshot PK

• On 2 Mar 2010 at 13:53:47, "Beaupre,AJ" (AJ.Beaupre.-a-.colostate.edu) sent the message
  

  
  The following message was posted to: PharmPK
  
  I'm curious if anyone has experience using the snapshot PK preclinical in vivo drug screening design.  If so, how did your results compare to full PK studies performed on the compound.
  
  I have a large library of compounds to screen and I'd like to avoid performing full PK screens.
  
  Thanks,
  AJ
  
  

  Back to the Top

• On 3 Mar 2010 at 01:19:57, Satya Jadhav (satya.jadhav.aaa.gmail.com) sent the message
  

  
  We use it routinely with a slight modification  and are happy with it for oral exposure (AUC) screening.
  [OK and Snapshot PK is?
  Oh, google helps again, this reference looks descriptive and useful
  http://www.gnf.org/assets/001/23052.pdf
  - db]
  
  

  Back to the Top

• On 3 Mar 2010 at 07:55:12, Toufigh Gordi (tgordi.at.yahoo.com) sent the message
  

  
  The following message was posted to: PharmPK
  
  Hi AJ,
  
  Sorry I won't be offering any answer to your question as I have very little "discovery phase" experience. However, I am interested to learn more and am curious to know what the PK experiments you are about to do in animals are aimed to reveal. What are the specific questions you, or other colleagues, are trying to answer by doing the PK experiments? What would be the PK criteria to select or deselect a compound?
  Thanks!
  
  Toufigh
  
  Toufigh Gordi, PhD
  Clinical Pharmacology, PK/PD analysis consultant
  www.tgordi.com
  
  

  Back to the Top

• On 3 Mar 2010 at 11:01:56, "Beaupre,AJ" (AJ.Beaupre.aaa.colostate.edu) sent the message
  

  
  The following message was posted to: PharmPK
  
  The lab is currently working with a novel antimicrobial class that is presenting a formulation challenge.  Previous PK attempts in a 5% ethanol/D5W (no solubility data, but visual inspection shows that this formulation allowed for minimal solubility) have yielded very low plasma levels of parent compound.  My hope is to find an optimal formulation in an effort to increase plasma levels.  We have yet to determine if antimicrobial activity is related to T/MIC or fAUC/MIC thus an improvement in either category would be welcome.  My hope is to use the snapshot PK paradigm to remove formulations that are less than optimal while keeping animals usage numbers down.
  
  Thanks,
  AJ
  
  

  Back to the Top

• On 4 Mar 2010 at 19:45:24, Satya Jadhav (satya.jadhav.-a-.gmail.com) sent the message
  

  
  AJ
  What is your route of administration ? How much sure you are in saying that low plasma levels of your test compound are just because of poor formulation?
  
  

  Back to the Top

• On 4 Mar 2010 at 21:07:08, "Beaupre,AJ" (AJ.Beaupre.aaa.ColoState.EDU) sent the message
  

  
  The following message was posted to: PharmPK
  
  Previous work was done with IV, IP, and PO routes with the 5% EtOH formulation.
  
  

  Back to the Top

Copyright 1995-2011 David W. A. Bourne (david@boomer.org)